We transfer biomedical research into the clinic.

The Fraunhofer Institute for Cell Therapy and Immunology IZI investigates and develops solutions to specific problems at the interfaces of medicine, life sciences and engineering. One of the institute‘s main tasks is to conduct contract research for companies, hospitals, diagnostic laboratories and research institutes operating in the field of biotechnology, pharma­ceuticals and medical engineering.

The Fraunhofer IZI develops, optimizes and validates methods, materials and products for the business units Cell and Gene Therapy, Drugs and Diagnostics. Its areas of competence lie in cell biology, immunology, drug biochemistry, bioanalytics and bioproduction as well as process development and automation. In these areas, research specifically focusses on the indications oncology, immunological diseases as well as infectious diseases and neurodegenerative diseases.

The institute works in close cooperation with hospital institutions and performs quality tests besides carrying out the GMP-compliant manufacture of clinical test samples. Furthermore, it helps partners obtain manufacturing licenses and permits.

Teasers Set

Business units

Jobs / career

Press

Publications

News

Technology for health monitoring of dairy cows successfully licensed out

A test system has been developed at Fraunhofer IZI to assess the health of dairy cows and identify sick animals in the herd at an early stage based on immunological biomarkers in the milk. With the company NovaTec Immundiagnostica GmbH, an industry partner has now been found that will ...

Producing vaccines without the use of chemicals

Producing vaccines is a tricky task – especially in the case of inactivated vaccines, in which pathogens must be killed without altering their structure. Until now, this task has generally involved the use of toxic chemicals. Now, however, an innovative new technology developed by Fraunhofer researchers – the first solution of its kind – will use electron beams ...

Fraunhofer IZI’s “Molecular Drug Biochemistry and Therapy Development” (MWT) project group was set up in October 2013 to explore and develop new molecular strategies for the treatment of neurodegenerative and inflammatory diseases. Over the course of its five-year start-up phase, the group has become a fully-fledged part of the research market and has positioned itself well for the future.

Fraunhofer Institute for Cell Therapy and Immunology IZI Strengthens Cooperation with Japanese Research and Industry Partners

On October 11, 2018, representatives from Fraunhofer IZI and the Japanese Society for Regenerative Medicine came together in Yokohama, Japan, on the occasion of the BioJapan 2018 conference, where they signed a memorandum of understanding.